BioVantra
Client Portal Request Information →
Services / Prostate Cancer Estimation and Mapping

Prostate Cancer
Estimation & Mapping.

A structured clinical synthesis that correlates mpMRI findings, AI-enhanced lesion analysis, biopsy and pathology, and cytomolecular data into a single planning-oriented report. It estimates tumor size, volume, location, extent, and therapeutic margin, and organizes lesion distribution into a lesion-level and whole-gland map of disease geography.

Request Information → Back to Services
Integrates
mpMRI · AI-enhanced lesion analysis · pathology
Perspective
Lesion-level & whole-gland
Delivery
Cancer mapping & correlation report
01 · What the service includes

Four components,
one cancer map.

Prostate Cancer Estimation and Mapping is a structured clinical synthesis. Imaging, tissue, and supportive inputs are correlated into one planning-oriented report — not a visual diagram alone. Estimation brings together tumor size, volume, location, extent, and therapeutic margin. Mapping organizes lesion distribution and disease geography at the lesion level and across the gland.

A

Imaging-based lesion estimation

mpMRI findings and AI-enhanced mpMRI lesion analysis are reviewed together to estimate lesion location, size, volume, and spatial extent across the prostate. This imaging-derived estimation forms the anatomic foundation of the map.

B

Pathology and biopsy correlation

Biopsy findings and pathology are correlated with the imaging estimation, and cytomolecular findings are incorporated when available. Tissue-based information anchors the map to what has actually been sampled and confirmed.

C

Structured cancer mapping

Lesion-level estimates and whole-gland context are organized into a structured map of disease distribution — laterality, focality, and spatial extent — so findings can be referenced consistently across the care team.

D

Therapeutic margin guidance

Where appropriate, the report includes therapeutic margin guidance intended to support focal therapy planning and broader treatment discussions. This is treatment-oriented interpretation, not a prescription of a surgical or ablative plan.

02 · Clinical relevance

A treatment-relevant
view of the disease.

The report is designed to help the care team see lesion size, location, laterality, focality, and spatial distribution organized in one place — and to position that view within the rest of the diagnostic picture. It complements mpMRI, pathology, cytomolecular findings, and genomic or risk tools; it does not replace them.

  • A

    Supports focal therapy planning

    Estimated extent, lesion distribution, and therapeutic margin guidance are organized so they can be referenced during focal therapy planning and related treatment discussions.

  • B

    May assist biopsy and treatment planning

    A consistent lesion-level and whole-gland view may assist biopsy targeting, re-biopsy decisions, and broader treatment planning by making the spatial picture easier to reference across encounters.

  • C

    Organizes lesion size, location, and focality

    Lesion-level estimates and whole-gland context are brought into one report, so size, location, laterality, and focality can be read together rather than reconciled across separate documents.

  • D

    Integrates across imaging and tissue

    mpMRI, AI-enhanced lesion analysis, biopsy, pathology, and cytomolecular findings are interpreted together. The map reflects the full picture rather than any single input in isolation.

  • E

    Supports multidisciplinary communication

    A structured synthesis gives urology, radiology, pathology, and other stakeholders a shared reference point when discussing the case, which may support more consistent multidisciplinary interpretation.

  • F

    Complements, does not replace

    This service is intended to complement mpMRI, pathology, cytomolecular findings, and genomic or risk tools, and to support physician judgment — not to substitute for any of them.

Connect with BioVantra

Talk to us about prostate cancer estimation and mapping.

We work with urology practices and multidisciplinary teams that use mpMRI, pathology, and cytomolecular or genomic data to plan prostate cancer care. Share a little about your setting and a member of our team will follow up to discuss how this service may fit into your workflow.

Request Information → Contact our team
Existing client? Access diagnostic reports and case history through the Client Portal
Emailcontact@biovantra.com
Phone(352) 861-2296
Fax(352) 671-2737
Address9401 SW Highway 200
STE 502
Ocala, FL 34481-9650